These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31808653)

  • 1. [Efficacy of 5-reductase inhibitors in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia].
    Nizov AN
    Urologiia; 2019 Dec; (5):156-160. PubMed ID: 31808653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Araki K; Naya Y; Inahara M; Suzuki F; Ota S; Tsuji H; Mikami K; Yanagisawa M; Awa Y; Suzuki H
    Int J Urol; 2014 Aug; 21(8):815-9. PubMed ID: 24735081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
    Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
    J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia?
    Alcántara-Montero A; Brenes-Bermúdez FJ
    Actas Urol Esp; 2016 May; 40(4):268-9. PubMed ID: 26774534
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.
    Toren P; Margel D; Kulkarni G; Finelli A; Zlotta A; Fleshner N
    BMJ; 2013 Apr; 346():f2109. PubMed ID: 23587564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride.
    Yoshida T; Kinoshita H; Yoshida K; Mishima T; Taniguchi H; Yanishi M; Komai Y; Yasuda K; Sugi M; Matsuda T
    Urology; 2016 May; 91():154-7. PubMed ID: 26826590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study.
    Matsukawa Y; Kato M; Funahashi Y; Majima T; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2017 Sep; 36(7):1809-1815. PubMed ID: 28102554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the effects of switching from dutasteride to tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms: A randomized, open-label, multicenter study.
    Matsumoto T; Hatakeyama S; Narita T; Yoneyama T; Hashimoto Y; Ohyama C
    Int J Urol; 2019 Apr; 26(4):522-523. PubMed ID: 30659664
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
    Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
    Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for failure of long-term dutasteride add-on treatment to alpha-adrenergic antagonist for patients with lower urinary tract symptoms and benign prostatic enlargement.
    Wada N; Abe N; Miyauchi K; Ishikawa M; Makino S; Kakizaki H
    Int Urol Nephrol; 2022 Jan; 54(1):31-36. PubMed ID: 34767140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction.
    Shigehara K; Miyagi T; Nakashima T; Izumi K; Kitagawa Y; Mizokami A; Koh E; Shimamura M; Namiki M
    Aging Male; 2016 Jun; 19(2):128-33. PubMed ID: 26890877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.
    D'Agate S; Chavan C; Manyak M; Palacios-Moreno JM; Oelke M; Michel MC; Roehrborn CG; Della Pasqua O
    World J Urol; 2021 Jul; 39(7):2635-2643. PubMed ID: 33337513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.
    D'Agate S; Wilson T; Adalig B; Manyak M; Palacios-Moreno JM; Chavan C; Oelke M; Roehrborn C; Della Pasqua O
    World J Urol; 2020 Feb; 38(2):463-472. PubMed ID: 31079189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment to Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Maeda T
    Int J Urol; 2014 Aug; 21(8):819-20. PubMed ID: 24942824
    [No Abstract]   [Full Text] [Related]  

  • 16. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
    Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Palacios JM; Vasylyev A; Manyak MJ
    World J Urol; 2017 Mar; 35(3):421-427. PubMed ID: 27334136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study.
    Matsukawa Y; Gotoh M; Kato M; Funahashi Y; Narita M; Mitsui K
    Int J Urol; 2014 Aug; 21(8):826-30. PubMed ID: 24661225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective observational study on the efficacy and tolerability of a complex of phytochemicals versus dutasteride in the treatment of Lower Urinary Tract Symptomps due to Benign Prostatic Hyperplasia.
    Saitta G; Mantovani FA; Calabrese B; Aliboni C; Di Paola G; Meazza AL; Seveso M
    Arch Ital Urol Androl; 2024 Oct; 96(3):12869. PubMed ID: 39356008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men.
    Haque N; Masumori N; Sakamoto S; Ye Z; Yoon SJ; Kuo HC; Brotherton B; Wilson T; Muganurmath C; McLaughlin M; Manyak M
    Int J Urol; 2018 Nov; 25(11):944-951. PubMed ID: 30198102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.